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Abstract
Background: In chronic hepatitis C, the fibrosis progression rates are extremely variable and can be influenced by
factors associated with the host, virus and environment. Among the associated metabolic factors, hepatic steatosis
is characterized by an accumulation of triglycerides in hepatocytes. In the host, genetic determinants of hepatic steatosis
are observed, such as single-nucleotide polymorphisms (SNPs) in the microsomal triglyceride transfer protein (MTTP)
gene. The MTTP -493G/T SNP appears to play an important role in the regulation of gene expression and influences
the plasma concentration of circulating low-density lipoprotein (LDL). The present study investigated the influence of
this SNP in the development of hepatic steatosis in patients with chronic hepatitis C and evaluated the association of
hepatic steatosis with certain characteristics of these patients and the hepatitis C virus (HCV).
Methods: Two hundred thirty-nine patients with chronic hepatitis C were genotyped for the MTTP -493G⁄T SNP by a
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The association between hepatic
steatosis and selected characteristics of the patient and virus was evaluated using bivariate and multivariate analyses.
Results: The most prevalent MTTP -493G/T genotype was GG (46%) followed by GT (43.5%) and TT (10.5%). Multivariate
analysis of the total cohort revealed associations between the presence of hepatic steatosis and inflammatory activity of
moderate to high intensity (P < 0.001), advanced age (P = 0.010), elevated gamma glutamyl transpeptidase (GGT) levels
(P = 0.010) and low LDL levels (P = 0.022). Hepatic steatosis was also associated with the TT/GT genotype of the MTTP
-493G⁄T SNP in patients infected with HCV genotype 3 (P < 0.001).
Conclusions: In chronic hepatitis C patients infected with HCV genotype 3 and with the TT/GT genotype of the MTTP
-493G/T SNP, a significant increase in hepatic steatosis was observed, which may indicate that this SNP has a significant
influence on the accumulation of triglycerides in hepatocytes. Furthermore, associations were observed between hepatic
steatosis and inflammatory activity of moderate to high intensity, advanced age, elevated GGT and low LDL levels.
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Background
The main characteristic of hepatitis C is liver inflamma-
tion caused by the hepatitis C virus (HCV). Approximately
3% of the world’s population may be infected with HCV,
which indicates that 170 million people are at risk of de-
veloping chronic liver disease [1]. HCV genotype 1 is the
most prevalent genotype worldwide and accounts for 83.4
million cases, and it is followed by genotype 3 [2]. HCV
infection is considered chronic after 6 months of HCV-
RNA persistence in the blood. The fibrosis progression
rates are extremely variable and can be influenced by fac-
tors associated with the host, virus and environment [3].
Hepatic steatosis is a metabolic factor characterized by
an accumulation of triglycerides in hepatocytes, and this
disorder has a significant impact on the progression of
liver fibrosis. The prevalence of steatosis in patients with
chronic hepatitis C is approximately 40% [4]. The genotype
of the virus may influence the likelihood of developing
steatosis, particularly HCV genotype 3, which is associated
with a more prevalent and severe steatosis relative to the
genotype non-3 [5]. Within HCV-seroconverted subjects,
greater changes in the lipid fractions were generally ob-
served in patients with HCV genotype 3 [6]. In the host,
genetic determinants of hepatic steatosis are observed such
as single-nucleotide polymorphisms (SNPs) in the micro-
somal triglyceride transfer protein (MTTP) gene and
patatin-like phospholipase-3 (PNPLA3) gene [5, 7].
The function of MTTP is related to the assembly and
secretion of low-density lipoproteins (LDLs), such as very
low-density lipoproteins (VLDLs) [5, 8, 9]. A functional
SNP in the promoter region of MTTP (−493G/T) has
been found to play an important role in the regulation of
gene expression and influences the concentration of circu-
lating LDL in the plasma of healthy individuals [10].
Zheng et al. [11] and Li et al. [12] conducted a meta-
analysis and concluded that the MTTP -493G/T SNP is
strongly associated with an increased risk of hepatic
steatosis, which may contribute to the development of
non-alcoholic fatty liver disease (NAFLD). Corroborating
these data, Hsiao et al. [13] found that MTTP SNPs, in-
cluding MTTP -493G/T, could modulate lipid homeostasis
and influence serum lipid levels and NAFLD risk. However,
the association between the MTTP -493G/T SNP and the
pathogenesis of steatosis associated with HCV has not been
established. The present study investigated the influence of
this polymorphism in the development of hepatic steatosis
in patients with chronic hepatitis C from São Paulo, Brazil
and evaluated the association between hepatic steatosis and
specific characteristics of these patients and HCV.
Methods
Study population
A retrospective study with 239 patients chronically in-
fected with HCV was conducted at the Clinical Hospital
of the School of Medicine, University of Sao Paulo
(HC-FMUSP), Sao Paulo, Brazil from January 2010 to
December 2012.
All patients presented with HCV-RNA, had undergone
a liver fragment histopathological analysis within the pre-
vious three years, were older than 18 years and were not
co-infected with hepatitis B virus (HBV) or acquired hu-
man immunodeficiency virus (HIV). The study protocol
conformed to the ethical guidelines of the 1975 Declar-
ation of Helsinki and was performed according to the
recommendations of the ethics committee of HC-FMUSP.
Clinical and laboratory assessments
The diagnosis of HCV was established based on a qualitative
HCV-RNA nested PCR. The serum levels of HCV-RNA
were evaluated using the Amplicor HCV Monitor 2.0 test
(Roche Diagnostic Systems, Branchburg, New Jersey, USA),
and the HCV genotypes were determined by the Line Probe
Assay using Versant HCV Genotype 2.0 (Immunogenetics,
Ghent, Belgium) according to standard methods.
An interview to evaluate the demographic data and po-
tential risk factors for acquiring the virus as well as a med-
ical consultation and the collection of 10 ml of peripheral
blood were conducted from 2010 to 2012. The following
characteristics were investigated: age, gender, weight,
height, and alcohol and tobacco consumption. The body
mass index (BMI) was calculated as the weight divided by
the height squared (kg/m2).
The biochemical tests included the following: alanine
aminotransferase (ALT) level, which was considered ele-
vated at ≥41 U/L; aspartate aminotransferase (AST) level,
which was considered elevated at ≥37 U/L; gamma glu-
tamyl transpeptidase (GGT) level, which was considered
elevated at ≥61 U/L; triglyceride level, which was consid-
ered elevated at >200 mg/dL; total cholesterol level, which
was considered elevated at >200 mg/dL; LDL level, which
was considered elevated at >130 mg/dL; high-density
lipoprotein (HDL) level, which was considered low at
<60 mg/dL; and VLDL level, which was considered
elevated at >40 mg/dL.
The fibrosis stage and inflammatory activity of the liver
were evaluated according to the METAVIR score [14].
The presence of steatosis was evaluated as described by
Kleiner et al. [15]. Perls’ staining with score of 0–4 was
applied to assess hepatic siderosis. Based on data from
the insulin secretion and fasting glucose analyses, the
HOMA-IR (homeostasis model assessment of insulin
resistance) index of the patients was calculated and pa-
tients who presented HOMA-IR ≥3.0 were considered
to have insulin resistance [16, 17].
SNP genotyping
Genomic DNA was extracted from 200 μL of serum using
a PureLink Genomic DNA Mini kit (Invitrogen - Life
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Technologies, Carlsbad, California, USA) according to the
manufacturer’s instructions. The SNP rs1800591 is located
at the position -493G/T in the promoter region of the
MTTP gene on human chromosome 4. For genotyping,
we performed polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP). The pro-
tocols were based on the descriptions of Karpe et al.
[10] and Bernard et al. [18], although certain thermal
cycling conditions and reagents were adjusted. The fol-
lowing primers were employed in the PCR assay: forward
5′ AGTTTCACACATAAGGACAATCATCTA 3′ and re-
verse 5′ GGATTTAAATTTAAACTGTTAATTCATATC
AC 3′. Amplification by PCR was conducted in a final
volume of 16.7 μL of reaction mix containing 8.3 μL of
GoTaq Green (Promega, Fitchburg, Wisconsin, USA),
5.3 μL of ultrapure water, 0.7 μL of each primer and
1.7 μL of DNA input. The annealing temperature was
adjusted to 55 °C. The PCR assay amplified a fragment
of 109 bp, and then 15 μL of this amplicon was incu-
bated with 1 μL of the endonuclease restriction enzyme
Hph1 (Hph1, 5000 U/ml; New England BioLabs, Ipswich,
Massachusetts, USA), 2 μL of buffer (1× NEBuffer 4) and
2 μL of ultrapure water under the following thermocycler
conditions: 37 °C for 3 h and inactivation at 65 °C for
20 min. The digested PCR products were subjected to
horizontal 4% agarose gel electrophoresis with 6 μL of
Diamond Dye (Promega, Fitchburg, Wisconsin, USA) in
0.5× TBE buffer at 120 V for 3 h and 30 min and were
analyzed using a UVIdoc HD2 Imaging System (Uvitec
Cambridge, Cambridge, United Kingdom). In the presence
of the wild-type allele (G), the restriction enzyme cleaves
the 109 bp fragment into two fragments of 89 bp and
20 bp. In the presence of the mutated allele (T), the en-
zyme cleavage site is eliminated, and the full-length
fragment (109 bp) remains intact.
Statistical analysis
The frequencies of steatosis were classified based on per-
sonal, clinical and qualitative laboratory characteristics.
Quantitative characteristics were classified based on the
presence of steatosis using the following measures: mean,
standard deviation, median, minimum and maximum
[19]. The odds ratio (OR) of each variable with the oc-
currence of steatosis was estimated with the respective
95% confidence intervals (CI) and bivariate tests using
simple logistic regression [20].
A multiple logistic regression model was used [20] for
steatosis and the variables that presented levels of sig-
nificance less than 0.10 (P < 0.10) in the bivariate tests.
The interaction between the type of HCV genotype and
mutation of the MTTP gene was tested, with only the
variables with a significance level of less than 0.05
(P < 0.05) maintained in the final models.
Qualitative characteristics were classified based on the
type of HCV genotype, and associations were verified with
the χ2 test [19]. The quantitative variables were classified
based on the type of HCV genotype and compared using
Student’s t-test [19].
The analyses were conducted using the software IBM-
SPSS for Windows version 20.0 (Chicago, Illinois, USA),
and data were tabulated using the software Microsoft
Excel 2003 (Redmond, Washington, USA). Tests were
performed with a significance level of 5%.
Results
For the 239 patients infected with HCV, 55 years was the
mean age (range: 29–83 years), 58.2% were female, and
40.6% reported blood transfusion as a potential risk factor
for acquiring HCV. Additionally, 19.3% of the patients re-
ported ingesting more than 20 g/day of alcohol and 29.7%
of the patients smoked more than 15 packets/day. Regard-
ing the BMI, the majority (39.9%) of the patients were
overweight (BMI = 25–29.9). The HCV genotype distribu-
tions were as follows: genotype 1 at 78.7%, 2 at 2.9%, 3 at
17.1% and 5 at 1.3%. The distribution of patients accord-
ing to the pathological characteristics of the liver fragment
was as follows: fibrosis 0 at 16.3%, 1 at 40.6%, 2 at 22.2%,
3 at 11.3% and 4 at 9.6%; inflammatory activity 0 at 1.3%,
1 at 33,1%, 2 at 50.6% and 3 at 15.1%; steatosis 0 at 52.3%,
1 at 34,3%, 2 at 11.3% and 3 at 2.1%; siderosis 0 at 78.2%,
1 at 4.2% and 2 at 17.6%.
To genotype the MTTP -493G/T SNP (rs1800591),
DNA fragment profiles were generated to identify the nor-
mal (wild-type) homozygous genotype (GG), the heterozy-
gous genotype (GT), and homozygous genotype carrying
copies of the mutated allele (TT) (Figure 1). The most
prevalent genotype was GG (46%) followed by GT (43.5%)
and TT (10.5%).
Table 1 shows that the presence of hepatic steatosis
alone was significantly more frequent in older patients
(P = 0.001), in patients with HCV genotype 3 (P = 0.029),
in patients with advanced fibrosis (grade 3–4) (P = 0.002),
and in patients with inflammatory activity of moderate to
high intensity (grade 2–3) (P < 0.001). ALT, AST, GGT
and BMI were significantly higher in patients with steato-
sis (P < 0.05), whereas cholesterol and LDL were signifi-
cantly lower in patients with steatosis (P = 0.022 and
P = 0.005, respectively). HOMA-IR ≥3.0 was associated
with the presence of steatosis (P = 0.011).
Advanced patient age was associated with an increased
risk of steatosis; in other words, with each additional
year of age the risk increased 4%. Patients with inflamma-
tory activity of moderate to high intensity had a 3.97-fold
greater risk of steatosis than patients without inflamma-
tory activity. Elevated GGT levels increased the risk of
steatosis, whereas elevated in LDL levels decreased the
risk of steatosis. The interaction between the type of HCV
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genotype and the presence of the MTTP mutation was
statistically significant. In patients with HCV genotype 3
and mutation (GT/TT) of the MTTP gene, the risk of
steatosis was 25.22-fold greater than in patients without
these associated characteristics (P < 0.001). Of note, the
isolated presence of HCV genotype 3 and the isolated
presence of the MTTP mutation did not significantly
increase the risk of steatosis (P = 0.080 and P = 0.116,
respectively) (Table 2).
Group analysis: HCV genotype 3 and genotype non-3
The patients were divided into two groups: HCV genotype
3 and genotype non-3 (including genotypes 1, 2 and 5). The
study group characteristics are described in Table 3. The
analysis of the two groups is presented in Tables 1 and 2.
Patients with HCV genotype 3 had significantly more
siderosis than patients with HCV genotype non-3
(P = 0.035), and the average cholesterol and LDL levels
of patients with HCV genotype 3 were significantly
lower (P = 0.007 and P = 0.024, respectively) (Table 3).
Finally, the multivariable analysis (Table 2) determined
the relationship between hepatic steatosis and different
MTTP -493G/T SNP genotypes in the patients with
HCV genotype 3. Because of the small number of patients
with the TT genotype, the patients with the GT and TT
genotypes were grouped together into GT/TT group.
Forty-one patients were analyzed to investigate the factors
associated with steatosis in the patients with HCV geno-
type 3. An association between genotype GT/TT of the
SNP and steatosis was observed in this group of patients.
Discussion
The results of the present study were used to investigate
the relationships among steatosis, chronic hepatitis C,
host factors and viral factors. The multivariate analysis
of a cohort of 239 Brazilian patients chronically infected
with HCV showed that the GT/TT genotype of the MTTP
-493G/T SNP (rs1800591) was associated with hepatic
steatosis in patients infected with HCV genotype 3, in a
total cohort of 239 Brazilian patients chronically infected
with HCV, including 198 patients infected with HCV
genotype non-3 and 41 infected with HCV genotype 3.
In the bivariate analysis of the total cohort, the presence
of hepatic steatosis was associated with HCV genotype 3.
The multivariate analysis indicated associations between
hepatic steatosis and inflammatory activity of moderate to
high intensity, advanced age, elevated GGT and low LDL
levels. However, our study presented certain limitations,
such as the small number of patients infected with HCV
Fig. 1 Restriction fragment length polymorphism (RFLP) analysis of
the 109 bp amplified product of the MTTP gene. Legend: 4% agarose
gel showing: (1) dominant homozygous for the normal GG allele, (2)
heterozygous GT, (3) recessive homozygous TT
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Table 1 Description of the occurrence of hepatic steatosis among patients with chronic hepatitis C according to the characteristics
evaluated and the results of the bivariate tests
Parameter Steatosis OR 95% CI P
Absent (n = 125) Present (n = 114) Low Upper
Age (years) 1.038 1.014 1.061 0.001
Mean ± SD 53.1 ± 11.6 58.2 ± 11.8
Median (min-max) 54 (30–76) 61 (29–83)
Gender, n (%) 0.079
Female 66 (47.5) 73 (52.5) 1.00
Male 59 (59) 41 (41) 0.63 0.37 1.06
HCV genotype, n (%) 0.029
Non-3 110 (55.6) 88 (44.4) 1.00
3 15 (36.6) 26 (63.4) 2.17 1.08 4.34
Fibrosisa, n (%) 0.002
0–2 109 (57.7) 80 (42.3) 1.00
3–4 16 (32) 34 (68) 2.90 1.50 5.61
Siderosis, n (%) 0.491
Absent 100 (53.5) 87 (46.5) 1.00
Present 25 (48.1) 27 (51.9) 1.24 0.67 2.30
Inflammatory activitya, n (%) <0.001
0–1 62 (75.6) 20 (24.4) 1.00
2–3 63 (40.1) 94 (59.9) 4.63 2.55 8.40
ALT (U/L) 1.008 1.002 1.014 0.012
Mean ± SD 54.1 ± 40.5 70 ± 51.4
Median (min-max) 44 (11–296) 54.5 (12–311)
AST (U/L) 1.013 1.005 1.022 0.003
Mean ± SD 42.1 ± 30.4 58.8 ± 45.5
Median (min-max) 33 (14–225) 46 (13–251)
GGT (U/L) 1.006 1.002 1.009 0.001
Mean ± SD 65.6 ± 61.1 113.8 ± 128.8
Median (min-max) 46 (8–361) 65.5 (10–733)
Cholesterol (mg/dL) 0.992 0.986 0.999 0.022
Mean ± SD 178.7 ± 43.8 166.2 ± 37.1
Median (min-max) 174 (104–399) 167.5 (69–252)
LDL (mg/dL) 0.989 0.981 0.997 0.005
Mean ± SD 101.8 ± 38.7 88.6 ± 31.1
Median (min-max) 99 (29–276) 86 (12–176)
HDL (mg/dL) 1.000 0.986 1.015 0.982
Mean ± SD 55.2 ± 17 55.2 ± 18.1
Median (min-max) 54 (25–101) 55 (21–110)
VLDL (mg/dL) 1.004 0.985 1.025 0.661
Mean ± SD 21.7 ± 11.7 22.4 ± 14
Median (min-max) 19 (7–76) 19 (5–105)
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genotype 3, which reduced the statistical power for testing
the hypotheses.
The bivariate logistic regression findings regarding the
association between hepatic steatosis and HCV genotype
3, age, fibrosis and BMI corroborate the findings of
Rubbia-Brandt et al. [21], who evaluated 755 patients with
chronic hepatitis C. Among these 755 patients, 178 had
HCV genotype 3, and steatosis was independently associ-
ated with age (P = 0.002), BMI, fibrosis, HCV genotype 3
and alcohol abuse (P < 0.001). The authors concluded that
hepatic steatosis is associated with liver fibrosis only in
patients infected with chronic hepatitis C with HCV
genotype 3 and that several factors may determine the
progression of liver fibrosis in patients infected with other
genotypes, such as age, prolonged alcohol use and possible
history of diabetes. In a study with 574 patients with HCV,
Patton et al. [22] observed that the degree of steatosis was
associated with the BMI, HCV genotype 3, age and dur-
ation of infection (P < 0.001). In another study of 86 pa-
tients who had steatosis, a higher prevalence was observed
in HCV genotype 3a infection (P < 0.01), and higher
serum levels of GGT were observed (P < 0.001), consistent
with the results of the multivariate analyses in the present
study [23]. In addition, the study by Kumar et al. [24] indi-
cated that the HCV genotype 3 (but not genotype 1) plays
a direct role in the pathogenesis of hepatic steatosis.
Our results for the associations between hepatic steato-
sis and HCV genotype 3, age, fibrosis and BMI are also in
accordance with those of Leandro et al. [25]. In addition,
we identified an association between hepatic steatosis and
inflammatory activity in patients infected with HCV (via
multiple logistic regression), which is also consistent with
the results of Leandro et al. [25], who conducted a robust
analysis of 3068 patients contained in 10 databases and
concluded that steatosis was associated with fibrosis in pa-
tients with chronic hepatitis C via inflammatory reactions
because hepatic inflammation can promote fibrogenesis in
patients with hepatic steatosis. Inflammatory activity was
also associated with hepatic steatosis only in HCV
genotype 1, whereas we did not observe this association
in the patients included in the HCV genotype non-3
group. In our study, inflammatory activity of moderate
to high intensity was present in similar proportions,
65.2 and 68.3%, of the HCV genotype non-3 and genotype
3 groups, respectively. Kobayashi et al. [26] evaluated the
clinical and histological statuses and virological character-
istics of 256 patients chronically infected with HCV geno-
types 1 and 2 to identify the factors associated with ALT
serum levels. ALT activity in the liver has been widely used
as a marker of liver inflammation. Elevated ALT levels in
the serum of the patients evaluated by Kobayashi et al.
[26] were strongly associated with severe hepatic in-
flammation and male gender, and they were also associ-
ated with higher HOMA-IR index values, low HDL
levels, and a higher degree of hepatic steatosis. The
Table 1 Description of the occurrence of hepatic steatosis among patients with chronic hepatitis C according to the characteristics
evaluated and the results of the bivariate tests (Continued)
Triglyceride (mg/dL) 1.001 0.997 1.005 0.670
Mean ± SD 105.9 ± 52.2 109.3 ± 70
Median (min-max) 97 (34–372) 92.5 (35–502)
BMI 1.077 1.011 1.147 0.021
Mean ± SD 26 ± 3.9 27.3 ± 4.5
Median (min-max) 25.7 (17.4–38.3) 26.4 (18.5–40.2)
HOMA-IR, n (%) 0.011
< 3 88 (59.1) 61 (40.9) 1.00
≥ 3 34 (41.5) 48 (58.5) 2.04 1.18 3.52
MTTP, n (%) 0.521
GG 60 (54.5) 50 (45.5) 1.00
GT/TT 65 (50.4) 64 (49.6) 1.18 0.71 1.97
Bivariate logistic regression, significance level of P < 0.10
aMetavir score
Table 2 Multivariate analysis of the characteristics that influenced
the presence of hepatic steatosis among patients with chronic
hepatitis C
Parameter OR 95% CI P
Low Upper
Age (years) 1.04 1.01 1.06 0.010
HCV Genotype 3 0.30 0.08 1.16 0.080
Inflammatory activity (2–3) 3.97 2.03 7.74 <0.001
GGT (U/L) 1.005 1.001 1.009 0.010
LDL (mg/dL) 0.990 0.981 0.999 0.022
MTTP (GT/TT) 0.60 0.31 1.14 0.116
HCV genotype 3 x MTTP (GT/TT) 25.22 4.24 150.09 <0.001
Multiple logistic regression, significance level of P < 0.05
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Table 3 Description of characteristics evaluated according to the type of HCV genotype (non-3 and 3) and the results of statistical tests
Parameter HCV genotype P
Non-3 (n = 198) 3 (n = 41) Total
Age (years) 0.231
Mean ± SD 55.2 ± 12.3 57.3 ± 9.7 55.5 ± 11.9
Median (min-max) 57 (29–83) 60 (31–71) 57 (29–83)
Gender, n (%) 0.769
Female 116 (58.6) 23 (56.1) 139 (58.2)
Male 82 (41.4) 18 (43.9) 100 (41.8)
Fibrosisa, n (%) 0.307
0–2 159 (80.3) 30 (73.2) 189 (79.1)
3–4 39 (19.7) 11 (26.8) 50 (20.9)
Siderosis, n (%) 0.035
Absent 160 (80.8) 27 (65.9) 187 (78.2)
Present 38 (19.2) 14 (34.1) 52 (21.8)
Inflammatory activitya, n (%) 0.700
0–1 69 (34.8) 13 (31.7) 82 (34.3)
2–3 129 (65.2) 28 (68.3) 157 (65.7)
ALT (U/L) 0.242
Mean ± SD 60.1 ± 44.4 69.5 ± 55.8 61.7 ± 46.6
Median (min-max) 47 (11–311) 50 (19–296) 47 (11–311)
AST (U/L) 0.487
Mean ± SD 49.3 ± 40 54 ± 34.9 50.1 ± 39.2
Median (min-max) 37 (13–251) 46 (21–163) 38 (13–251)
GGT (U/L) 0.670
Mean ± SD 89.9 ± 99.6 82.4 ± 113.8 88.6 ± 102
Median (min-max) 56 (8–733) 41 (13–628) 50 (8–733)
Cholesterol (mg/dL) 0.007
Mean ± SD 176 ± 41.4 157 ± 36.4 172.7 ± 41.2
Median (min-max) 174.5 (69–399) 160 (81–244) 170 (69–399)
LDL (mg/dL) 0.024
Mean ± SD 97.9 ± 36.8 84 ± 28.5 95.5 ± 35.8
Median (min-max) 97.5 (12–276) 81 (34–157) 93 (12–276)
HDL (mg/dL) 0.232
Mean ± SD 55.8 ± 18 52.2 ± 14.6 55.2 ± 17.5
Median (min-max) 55.5 (21–110) 50 (26–89) 54 (21–110)
VLDL (mg/dL) 0.478
Mean ± SD 22.3 ± 13.2 20.8 ± 10.8 22.1 ± 12.8
Median (min-max) 19 (5–105) 17 (7–50) 19 (5–105)
Triglyceride (mg/dL) 0.261
Mean ± SD 109.5 ± 63.4 97.7 ± 48.9 107.5 ± 61.2
Median (min-max) 95 (34–502) 84 (36–250) 94 (34–502)
BMI 0.891
Mean ± SD 26.6 ± 4.3 26.5 ± 4.2 26.6 ± 4.2
Median (min-max) 26.0 (17.4–39.2) 25.7 (18.5–40.2) 25.9 (17.4–40.2)
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authors hypothesized that specific metabolic factors
may originate from the host rather than from the virus.
We observed an association between hepatic steatosis
and insulin resistance only in the total cohort of patients
infected with HCV by bivariate logistic regression.
Fartoux et al. [27] found that insulin resistance was asso-
ciated with steatosis in patients with HCV genotype 1
but not in patients infected with genotype 3 (P = 0.001),
which was surprising because steatosis is usually severe
in these patients. Fartoux et al. [27] concluded that in-
creasing circulating insulin is a risk factor for fibrosis de-
velopment in chronic hepatitis C patients because of
insulin resistance-induced steatosis. In the present study,
insulin resistance was not associated with the viral geno-
type. A study conducted in Spain with 159 patients
showed that insulin resistance was higher in patients in-
fected with genotype 1 than in those infected with geno-
type 3a (P = 0.003), whereas in patients infected with
genotype 1, a correlation was observed between insulin
resistance and steatosis (P = 0.001) [28]. Hui et al. [29]
studied 260 patients with chronic hepatitis C, and the
independent predictors for the degree of hepatic steato-
sis were HCV genotype 3 (P = 0.001), BMI (P = 0.002),
portal inflammation (P = 0.03) and cholesterol level (a
negative association; P = 0.004). We also found in bivari-
ate logistic regression that the presence of hepatic stea-
tosis alone was associated with HCV genotype 3, BMI,
inflammatory activity of moderate to high intensity, and
lower levels of cholesterol and LDL. The inflamma-
tory activity and low LDL levels remained associated
with steatosis in multiple logistic regression. More-
over, Hui et al. [29] also found that insulin resistance
is an independent predictor for the degree of fibrosis
(P < 0.001) and fibrosis progression rate (P = 0.03).
The data found in our study and in the cited studies
may support the hypothesis that steatosis is associated
with insulin resistance and can contribute to fibrosis
progression.
Siderosis did not influence hepatic steatosis, but in the
group analysis of HCV genotype 3 and genotype non-3,
the presence of siderosis was significantly associated
with the HCV genotype 3 group. Adinolfi et al. [23] also
observed no association of hepatic iron storage with
steatosis, but in contrast to our findings, there was no
difference in iron storage between patients infected with
HCV genotype 3a and 1a.
Hepatic steatosis was also associated with the GT/TT
genotype of the MTTP -493G/T SNP in patients with
chronic hepatitis C and HCV genotype 3. In patients with
HCV genotype 3 and the MTTP mutation (GT/TT), the
risk of steatosis was 25.22 times higher than in patients
without these associated characteristics. Zampino et al. [8]
and Mirandola et al. [30] evaluated liver biopsies, labora-
tory tests and MTTP -493G/T SNP presence in patients
with chronic hepatitis C and indicated that the MTTP
protein has a pathogenic role in the development of fat ac-
cumulation in the liver. Zampino et al. [8] found an asso-
ciation between the T allele of the polymorphism and high
degrees of fatty liver accumulation in patients infected
with HCV genotype 3; conversely, Mirandola et al. [30]
found that the GT/TT MTTP genotype was the main risk
factor associated with a higher degree of steatosis in HCV
genotype non-3. Two other studies reported that the func-
tional -493G/T SNP did not influence the development of
hepatic steatosis in patients with chronic hepatitis C and
HCV genotype 3 [7, 31]. However, in a study with 174
Brazilian patients from the northeastern region, the G
allele was more often present in patients infected with
genotype 1 who had higher levels of fibrosis. Additionally,
the GG and GT genotypes were considered independent
protective factors against steatosis in patients with chronic
hepatitis C and HCV genotype 1 and non-1 [32]. Finally,
Saad et al. [9] also studied this polymorphism, although
not in relation to steatosis, and they reported an asso-
ciation between the GT and TT genotypes and severe
fibrosis and cirrhosis (P = 0.0001).
Conclusions
Our results provide evidence that in patients with chronic
hepatitis C the interaction between HCV genotype 3 and
the GT/TT genotype (as opposed to the GG genotype) of
the MTTP -493G/T SNP increases the risk of steatosis by
25.22-fold, which may indicate that this SNP has a sig-
nificant influence on the accumulation of triglycerides
Table 3 Description of characteristics evaluated according to the type of HCV genotype (non-3 and 3) and the results of statistical tests
(Continued)
HOMA-IR, n (%) 0.771
< 3 124 (64.9) 25 (62.5) 149 (64.5)
≥ 3 67 (35.1) 15 (37.5) 82 (35.5)
MTTP, n (%) 0.183
GG 95 (48) 15 (36.6) 110 (46)
GT/TT 103 (52) 26 (63.4) 129 (54)
Associations with qualitative variables were verified with the χ2 test, and comparisons of quantitative variables were performed with Student’s t-test, significance level of P < 0.10
aMetavir score
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in hepatocytes. Significant associations were also observed
between hepatic steatosis and inflammatory activity of
moderate to high intensity, advanced age, elevated GGT
and low LDL levels. Additional studies on other SNPs
of this gene and other genes must be performed to de-
termine whether they are significant risk factors for the
predisposition to develop hepatic steatosis in patients
with chronic hepatitis C.
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